Dr. Kwok Gin Wai - Medical Oncology
Specialist in Medical Oncology
Highlights
- MCHK RegisteredVerified
- Specialist in Medical OncologyBachelor of Medicine and Bachelor of Surgery (MBBS) · Hong Kong College of Physicians · Medical degree 2010
- InsuranceBeing compiled｜See details
About
Dr. Kwok Gin Wai is a registered Medical Oncology specialist in Hong Kong.
Education
Specialist in Medical Oncology
- Bachelor of Medicine and Bachelor of Surgery (MBBS)Bachelor of Medicine and Bachelor of Surgery (MBBS)2010
Hong Kong Academy of Medicine fellowships
- FHKCPFellow, Hong Kong College of Physicians
Source: Hong Kong Academy of Medicine Fellows Register, checked 12 Sep 2026
Insurance
Insurance plans being compiled
We're collecting insurance plan data per clinic. For confirmation, contact the clinic directly.
Are you Dr. Kwok Gin Wai? Claim page and update insurance →
FAQ
Is Dr. Kwok Gin Wai any good?
Dr. Kwok Gin Wai is a registered Medical Oncology specialist in Hong Kong. Qualifications and registration come from the Hong Kong Medical Council. ok.med does not rate or rank doctors.
What does Dr. Kwok Gin Wai do?
Dr. Kwok Gin Wai practises in Medical Oncology.
Are you Dr. Kwok Gin Wai? Claim this page to update and manage.
ClaimResearch and publications
7 papers
Filter by paper topic
Topics come from medical classifications on these PubMed papers, not from the doctor's listed services.
- High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis.Thyroid : official journal of the American Thyroid Association · 2025
- Role of Circulating Tumor DNA Tumor Fraction in Advanced Non-Small Cell Lung Cancer and Its Impact on Patient Treatment Outcomes: A Prospective Real-World Study.JCO precision oncology · 2025
- Response to Kakudo et al.: "High Rates of Unnecessary Surgery for Indeterminate Thyroid Nodules in the Absence of Molecular Test and the Cost-Effectiveness of Utilizing Molecular Test in an Asian Population: A Decision Analysis".Thyroid : official journal of the American Thyroid Association · 2025
- A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab, lenvatinib, carboplatin and pemetrexed in patients with metastatic non-small cell lung cancer harbouring targetable genomic alterations who progressed on standard tyrosine kinase inhibitors.Investigational new drugs · 2025
- Fulminant tumour lysis syndrome after nivolumab and ipilimumab treatment for hepatocellular carcinoma.Journal of hepatology · 2025
- Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer: a pilot study.Postgraduate medical journal · 2022
- Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy.Postgraduate medical journal · 2019
Publication data comes from PubMed / Europe PMC and is matched automatically by name and affiliation. Every entry links to the source.
For reference only. Not medical advice. Read full disclaimer